MPN Specialist Explains PTG-300 and Clinical Trial for PV Patients

by David Wallace

Hepcidin Mimetic PTG-300 Promising Treatment for PV

How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV?  How does iron deficiency play a role in polycythemia vera?  What are the goals of this treatment?  Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David Wallace, discussing early Phase 2 clinical trial results on PTG-300.

Check out the video to find out more about this new treatment for polycythemia vera.  More details on this trial can be found on clinicaltrials.gov.

This program is sponsored by Protagonist Therapeutics, Inc.  This organization has no editorial control, it is produced solely by PV Reporter.


 

About David Wallace

Founder of PV Reporter, a resource for Myeloproliferative Neoplasm (MPN) patients and caregivers. After being diagnosed with Polycythemia Vera (PV) in 2009, I utilized social media to connect with "informed patients" and develop a better understanding of emerging treatment options. My philosophy on patient care is straight forward - "educating the patient is essential, so the patient can guide their physician to meet his or her needs." PV Reporter is a comprehensive resource hub giving visitors vital tools to become "empowered patients."

error: Content is protected !